Temozolomide treatment achieved an overall response rate of 21.4% and a disease control rate of 35.8% in patients with metastatic adrenocortical cancer.
Does temozolomide with or without mitotane improve outcomes in patients with advanced adrenocortical cancer receiving second and subsequent lines of treatment?
In heavily pretreated patients with advanced adrenocortical cancer, temozolomide with or without mitotane showed a favorable toxicity profile and provided a disease control rate of ≥6 months in 21.9% of patients.
Absolute Event Rate: 0% vs 0%
Background: Currently there is no standard options have been established for 2nd and subsequent lines for advanced adrenocortical cancer (ACC).A retrospective data showed that the combination of temozolomide (Tem) and mitotane (M) demonstrated promising results.The objective response rate (ORR) was 21.4% and the disease control rate (DCR) -35.8%.We evaluate the effectiveness of Tem +/-M in real-world practice.Methods: This single-center study included patients (pts) 18 years who received Tem 150 mg/m 2 on days 1-5 every 4 weeks M for 2nd and subsequent lines for advanced ACC.We assessed the ORR, progression-free survival (PFS), overall survival (OS), disease control rate (DCR) of 6 months, and safety.Recruitment at N.N.
Zhulikov et al. (Sun,) reported a other. Temozolomide treatment achieved an overall response rate of 21.4% and a disease control rate of 35.8% in patients with metastatic adrenocortical cancer.